Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for PFE
-0.22 (-0.63%)
Real-time:   12:19PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 33.71 - 34.07
52 week 28.25 - 37.39
Open 33.94
Vol / Avg. 6.37M/18.34M
Mkt cap 205.81B
P/E 29.97
Div/yield 0.30/3.55
EPS 1.13
Shares 6.07B
Beta 0.87
Inst. own 72%
Nov 1, 2016
Q3 2016 Pfizer Inc Earnings Call - 10:00AM EDT - Add to calendar
Nov 1, 2016
Q3 2016 Pfizer Inc Earnings Release Add to calendar
Sep 13, 2016
Pfizer Inc at Morgan Stanley Global Healthcare Conference
Sep 8, 2016
Pfizer Inc at Wells Fargo Securities Healthcare Conference
Aug 22, 2016
Pfizer Inc to acquire Medivation Inc - M&A Call - Webcast
Aug 2, 2016
Q2 2016 Pfizer Inc Earnings Call - Webcast
Aug 2, 2016
Q2 2016 Pfizer Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Jul '16) 2015
Net profit margin 15.48% 14.28%
Operating margin 19.78% 21.14%
EBITD margin - 38.46%
Return on average assets 4.89% 4.16%
Return on average equity 12.87% 10.22%
Employees 97,900 -
CDP Score - 90 B


235 E 42ND ST
NEW YORK, NY 10017-5703
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel. Its commercial operations consist of two businesses: Innovative Products business and Established Products business. The Innovative Products business consists of two segments: the Global Innovative Pharmaceutical segment (GIP) and the Global Vaccines, Oncology and Consumer Healthcare segment (VOC). The Established Products business consists of the Global Established Pharmaceutical segment (GEP). Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Frank A D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 58
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business, Global Innovative Pharma Business
Age: 53
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 57
Bio & Compensation  - Reuters
John D. Young Group President - Global Established Pharma Business
Age: 51
Bio & Compensation  - Reuters
Rady A. Johnson II Executive Vice President, Chief Compliance and Risk Officer
Age: 54
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 50
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 60
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Anthony J. Maddaluna Executive Vice President, President - Pfizer Global Supply
Age: 63
Bio & Compensation  - Reuters